SEC For	m 4																
FORM 4 UNITED				TED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL	
Section obligat	this box if no lo n 16. Form 4 or ions may contir tion 1(b).	ed purs	TOF CHANGES IN BENEFICIAL OWNER								CMB Number: 3235-0287 Estimated average burden hours per response: 0.5			en 📗			
1. Name and Address of Reporting Person* LINK WILLIAM J PHD (Last) (First) (Middle)					2. I <u>Ta</u> 3. [or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS] 3. Date of Earliest Transaction (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)			
C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160						06/15/2021											
(Street) IRVINE CA 92618					4.1	Line)									vidual or Joint/Group Filing (Check Applicabl Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) Date (Month/D						Execution Dat			e, Transaction Dispos Code (Instr. 5)		Disposed	rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		Securities I Beneficially (Owned Following (Reported		Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	4. Transa Code (1 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)			nd 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$35.26	06/15/2021			A		10,000		(1)	0	6/15/2031	Common Stock	10,000	\$0.00	10,000	D	
Stock Option (right to buy)	\$35.26	06/15/2021			Α		10,000		(2)	0	6/15/2031	Common Stock	10,000	\$0.00	10,000	D	

Explanation of Responses:

1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

2. Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

Remarks:

/s/ Leo Greenstein

** Signature of Reporting Person

06/17/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.